Course Details | Pharmacy Academy

Management of HR+ HER2- Metastatic Breast Cancer

The management of hormone receptor-positive (HR+) HER2-negative metastatic breast cancer focuses on targeted therapies and systemic treatments. Endocrine therap...

Mahmoud Nouh

English

Certificate Course

27 Students

00h 00m

Course Overview

The management of hormone receptor-positive (HR+) HER2-negative metastatic breast cancer focuses on targeted therapies and systemic treatments. Endocrine therapy, such as aromatase inhibitors or selective estrogen receptor modulators (SERMs), is often the first line of treatment. In cases of disease progression, targeted agents like CDK4/6 inhibitors may be added to enhance treatment efficacy. Chemotherapy may be considered when hormonal therapies are no longer effective. Regular monitoring and personalized treatment plans are crucial to address the unique characteristics of each patient's cancer, aiming to improve quality of life and prolong survival. Multidisciplinary care, including palliative support, is essential for optimal management.

FAQ

Join the course then click on the camera icon shown below

Course curriculum

Online Lecture

Requirment

Outcomes

Improved Survival Rates: With effective treatment strategies, including endocrine therapy and targeted agents, many patients experience extended overall survival compared to historical data.
Enhanced Quality of Life: Targeted therapies often have fewer side effects than traditional chemotherapy, leading to better quality of life during treatment, with manageable symptoms and improved daily functioning.
Disease Stabilization: Many patients achieve disease stabilization or a partial response to treatment, allowing for prolonged periods without disease progression, which can be critical for maintaining life quality and personal goals.